Diagnostic Market Access & Reimbursement
Protect Revenue for the Tests That Drive Better Patient Outcomes
Diagnostic companies face a unique reimbursement challenge: groundbreaking tests can be clinically validated but still denied by payers. Appeal Health helps diagnostic organizations navigate market access barriers, protect reimbursement for molecular and genetic testing, and recover revenue from complex claim denials.
Why Diagnostic Reimbursement Is Under Pressure
Advanced diagnostics face reimbursement barriers that traditional billing approaches can't solve.
Payer Coverage Gaps for New Tests
Novel molecular diagnostics and genetic tests often lack established coverage policies. Payers deny claims citing experimental status, medical necessity, or documentation gaps — even when clinical evidence supports the test.
- Coverage policy uncertainty
- Experimental status denials
- Inconsistent payer interpretations
Complex Prior Authorization Requirements
Specialty diagnostic tests frequently require prior authorization with extensive clinical documentation. When authorization processes are inconsistent across payers, revenue delays and denials compound.
Reimbursement Erosion Over Time
Even tests with established coverage face gradual reimbursement erosion through rate changes, coding updates, and shifting medical necessity criteria that go undetected until revenue impact is significant.
Every denied claim represents more than paperwork — it's delayed care, lost revenue, and unnecessary friction.
Appeal Health helps teams see risk earlier and act before denial becomes loss.
Why Traditional Billing Falls Short for Diagnostics
Standard denial management wasn't built for the complexity of diagnostic reimbursement.
Generic Appeal Templates Don't Work
Molecular and genetic test appeals require specific clinical evidence, payer policy citations, and medical necessity arguments that generic templates can't provide.
No Visibility Into Payer-Specific Diagnostic Policies
Without intelligence on how individual payers handle specific test codes, diagnostic companies can't anticipate or prevent denials before they happen.
How Appeal Health Supports Diagnostic Market Access
Payer Policy Mapping for Diagnostics
Appeal Health maps payer coverage policies specific to molecular diagnostics, genetic testing, and specialty lab services — surfacing where coverage exists and where gaps create risk.
- Test-specific coverage analysis
- Payer policy gap detection
- Coverage determination tracking
Evidence-Based Diagnostic Appeals
Appeals are generated with clinical evidence, payer-specific policy citations, and medical necessity arguments tailored to diagnostic test categories.
Reimbursement Variance Monitoring
Track reimbursement trends by test type, payer, and denial reason to detect erosion early and protect revenue before write-offs accumulate.
- Test-level reimbursement tracking
- Payer behavior trend analysis
- Early warning on rate changes
Measurable Diagnostic Reimbursement Outcomes
Increased Overturn Rates for Complex Tests
Stronger, evidence-based appeals built on payer-specific intelligence lead to higher overturn rates for molecular diagnostics and genetic testing claims.
Proactive Market Access Strategy
Turn denial data into market access intelligence — understanding which payers support which tests, where coverage gaps exist, and how to position for better reimbursement.
- Payer coverage landscape visibility
- Data-driven market access decisions
- Reduced time to reimbursement
Enterprise-Grade Security & Compliance
HIPAA Compliant
Full compliance with healthcare data privacy regulations
Human-in-the-Loop
Supports teams — doesn't replace judgment
SOC 2 Pending
Enterprise security examination in progress
Protect Reimbursement for the Tests That Matter
Appeal Health helps diagnostic companies navigate market access challenges and recover revenue from complex claim denials.
Learn how a denial management platform works
Or email us: info@appeal.health